Agenus Inc news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

AGEN 2.55 +0.14 (5.81%)
price chart
Why Agenus Inc. Shares Tumbled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Agenus Inc (NASDAQ:AGEN) Looses Sheen After Lung Cancer Trial Data ...  GSPInsider
Ahead of the Bell: Agenus shares tumble  Businessweek
Related articles »  
Why Agenus (AGEN) Is Down Big Today
"We rate AGENUS INC (AGEN) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the ...
Earnings Estimates Moving Higher for Agenus (AGEN): Time to Buy?  Zacks.com
Related articles »  
News Recap - Agenus Inc (NASDAQ:AGEN), Synthetic Biologics, Inc ...
Las Vegas, NV - 16 April 2014 - (Tech Sonian) - Agenus Inc (NASDAQ:AGEN) declared the closing of its formerly reported underwritten registered public offering of common stock.
Agenus Inc (NASDAQ:AGEN) Receives �Buy� Rating
Dallas, Texas 03/26/2014 (FINANCIALSTRENDS) - Maxim Group has reaffirmed their �buy� rating on Agenus Inc (NASDAQ:AGEN) shares in the report that was issued to investors.
Maxim Group Reiterates "Buy" Rating for Agenus (AGEN)  Mideast Time
Related articles »  
Stocks in the Spotlight - Agenus Inc (AGEN), Banco Santander Brasil SA (ADR ...
Las Vegas, NV - April 16, 2014 - (Tech Sonian) �Agenus Inc(NASDAQ:AGEN)is a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants.
Related articles »  
Micro-cap Volatile Stocks: The Wet Seal (NASDAQ:WTSL), Agenus Inc ...
The Wet Seal, Inc. (NASDAQ:WTSL) rebounded on the last day of the trading week on 28th after investors found the stock to be priced appropriately, post its nearly 23 percent dip in valuation ever since it reported its 4Q and full year operational ...
Related articles »  
Trend Analysis Report-Agenus Inc (AGEN), Mechel OAO (ADR) (MTL), E ...
Agenus Inc (NASDAQ:AGEN) decreased -4.67% and closed at $3.06 on a traded volume of 1.33 million shares, in comparison to 1.41 million shares of average trading volume.
Related articles »  
Big Movers: Agenus Inc (NASDAQ:AGEN), CytRx Corporation (NASDAQ:CYTR ...
New York, NY - (MARKET NEWS CALL) - 4/02/2014� Agenus Inc (NASDAQ:AGEN)'s shares dropped 6.34% to $3.10. The company on Apr. 1 announced that GlaxoSmithKline's (GSK) MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled ...
Update on GSK'S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Non ...  MarketWatch
UPDATE 1-GlaxoSmithKline throws in towel on lung cancer vaccine trial  Reuters
Related articles »  
Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical ...
Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) ...
News Recap: Agenus Inc (AGEN), Gafisa SA (ADR) (NYSE:GFA), Earthlink ...
Manhattan, NY- April 02, 2014 - (Techsonian) - Agenus Inc (NASDAQ:AGEN) announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, presented on Agenus' checkpoint modulator portfolio and immuno-oncology strategy at the 4th Annual ...
Related articles »